Page last updated: 2024-11-10

eleostearic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

eleostearic acid: RN given refers to cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5385589
CHEBI ID180171
SCHEMBL ID1271926
SCHEMBL ID20787982
MeSH IDM0046163

Synonyms (24)

Synonym
CHEBI:180171
(9e,11e,13z)-octadeca-9,11,13-trienoic acid
catalpic acid
nsc407903
eleostearic acid, .beta.-
elaeosteraric acid
9,13-octadecatrienoic acid
13296-76-9
nsc-407903
eleostearic acid
LMFA01030883
9e,11e,13z-octadecatrienoic acid
18:3(9e,11e,13z)
4337-71-7
9(e),11(e),13(z)-octadecatrienoic acid
SCHEMBL1271926
Q646902
SCHEMBL20787982
trans,trans,cis-9,11,13-octadecatrienoic acid
DTXSID901026854
27d2cw7k2p ,
9,11,13-octadecatrienoic acid, (z,e,e)-
9,11,13-octadecatrienoic acid, (9e,11e,13z)-
unii-27d2cw7k2p

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"1% or 1% CPO for 4 weeks, starting one week before the first dosing of AOM."( Catalpa seed oil rich in 9t,11t,13c-conjugated linolenic acid suppresses the development of colonic aberrant crypt foci induced by azoxymethane in rats.
Hosokawa, M; Kohno, H; Miyamoto, S; Miyashita, K; Suzuki, R; Tanaka, T; Yasui, Y, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
octadecatrienoic acidAny trienoic fatty acid having eighteen carbons.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.33)18.7374
1990's3 (4.00)18.2507
2000's21 (28.00)29.6817
2010's43 (57.33)24.3611
2020's4 (5.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]